About the Authors

David Aviezer

Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel

Einat Brill-Almon

Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel

Yoseph Shaaltiel

Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel

Sharon Hashmueli

Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel

Daniel Bartfeld

Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel

Sarah Mizrachi

Affiliation Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel

Yael Liberman

Affiliation Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel

Arnold Freeman

Affiliation Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel

Ari Zimran

Affiliation Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel

Eithan Galun

eithang@hadassah.org.il

Affiliation Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel

Competing Interests

David Aviezer, Einat Brill-Almon, Yoseph Shaaltiel, Sharon Hashmueli, and Daniel Bartfeld are all employed by Protalix (http://www.protalix.com) the company which sponsored the study and also hold the license for the product. As such holds shares in the company. As aponsors and funders of the study Protalix employees (listed above) had a role in study design and review of data analysis. Eithan Galun was an adviser to Protalix. Ari Zimran is a paid consultant of Protalix. All other authors declare no competing financial interests.

Author Contributions

Conceived and designed the experiments: DA EBA AZ EG. Performed the experiments: SM YL AF EG. Analyzed the data: DA EBA SH AZ EG. Contributed reagents/materials/analysis tools: EBA YS SH DB EG. Wrote the paper: DA SH AZ EG.